Thomas Zeller

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8475889/publications.pdf

Version: 2024-02-01

91 papers	10,291 citations	46918 47 h-index	48187 88 g-index
91 all docs	91 docs citations	91 times ranked	3089 citing authors

#	Article	IF	Citations
1	Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg. New England Journal of Medicine, 2008, 358, 689-699.	13.9	732
2	Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. New England Journal of Medicine, 2015, 373, 145-153.	13.9	558
3	Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease. Circulation, 2015, 131, 495-502.	1.6	554
4	Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal Disease. Circulation: Cardiovascular Interventions, 2011, 4, 495-504.	1.4	514
5	Drug-Eluting and Bare Nitinol Stents for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery:Long-term Results From the SIROCCO Trial. Journal of Endovascular Therapy, 2006, 13, 701-710.	0.8	468
6	Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery. Circulation, 2016, 133, 1472-1483.	1.6	426
7	Peripheral arterial calcification: Prevalence, mechanism, detection, and clinical implications. Catheterization and Cardiovascular Interventions, 2014, 83, E212-20.	0.7	391
8	The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) Trial for Femoropopliteal Revascularization. JACC: Cardiovascular Interventions, 2014, 7, 10-19.	1.1	346
9	Drug-Eluting Balloon Versus StandardÂBalloon Angioplasty for Infrapopliteal Arterial Revascularization inÂCritical LimbÂIschemia. Journal of the American College of Cardiology, 2014, 64, 1568-1576.	1.2	327
10	Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions. Journal of the American College of Cardiology, 2015, 66, 2329-2338.	1.2	325
11	Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions. Journal of the American College of Cardiology, 2013, 61, 2417-2427.	1.2	307
12	A Prospective Randomized Multicenter Comparison of Balloon Angioplasty and Infrapopliteal Stenting With the Sirolimus-Eluting Stent in Patients With Ischemic Peripheral Arterial Disease. Journal of the American College of Cardiology, 2012, 60, 2290-2295.	1.2	233
13	Angioplasty of Femoral-Popliteal Arteries With Drug-CoatedÂBalloons. JACC: Cardiovascular Interventions, 2015, 8, 102-108.	1.1	230
14	Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. Journal of Vascular Surgery, 2012, 55, 390-398.	0.6	228
15	Limb Salvage Following Laser-Assisted Angioplasty for Critical Limb Ischemia:Results of the LACI Multicenter Trial. Journal of Endovascular Therapy, 2006, 13, 1-11.	0.8	221
16	Lower Extremity Revascularization Using Directional Atherectomy. JACC: Cardiovascular Interventions, 2014, 7, 923-933.	1.1	210
17	A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet, The, 2018, 392, 1541-1551.	6.3	196
18	Mortality Not Correlated With PaclitaxelÂExposure. Journal of the American College of Cardiology, 2019, 73, 2550-2563.	1.2	195

#	Article	IF	Citations
19	Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	180
20	Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries. Circulation: Cardiovascular Interventions, 2018, 11, e005891.	1.4	166
21	Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. European Heart Journal, 2011, 32, 2274-2281.	1.0	162
22	Sirolimus-Eluting Stents for Treatment of Infrapopliteal Arteries Reduce Clinical Event Rate Compared to Bare-Metal Stents. Journal of the American College of Cardiology, 2012, 60, 587-591.	1.2	152
23	Paclitaxel-Coated Balloon in InfrapoplitealÂArteries. JACC: Cardiovascular Interventions, 2015, 8, 1614-1622.	1.1	147
24	Endovascular Treatment of Common Femoral Artery Disease. Journal of the American College of Cardiology, 2011, 58, 792-798.	1.2	139
25	Paclitaxel-Releasing Balloon in Femoropopliteal Lesions Using a BTHC Excipient. Journal of Endovascular Therapy, 2015, 22, 14-21.	0.8	134
26	AMS INSIGHTâ€"Absorbable Metal Stent Implantation for Treatment of Below-the-Knee Critical Limb Ischemia: 6-Month Analysis. CardioVascular and Interventional Radiology, 2009, 32, 424-435.	0.9	131
27	Drug-Coated Balloons vs. Drug-Eluting Stents for Treatment of Long Femoropopliteal Lesions. Journal of Endovascular Therapy, 2014, 21, 359-368.	0.8	129
28	Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis. Circulation, 2015, 132, 2230-2236.	1.6	128
29	Determinants of Longâ€Term Outcomes and Costs in the Management of Critical Limb Ischemia: A Populationâ€Based Cohort Study. Journal of the American Heart Association, 2018, 7, e009724.	1.6	113
30	Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease. Journal of the American College of Cardiology, 2019, 73, 667-679.	1.2	111
31	Treatment of Femoropopliteal In-Stent Restenosis With Paclitaxel-Eluting Stents. JACC: Cardiovascular Interventions, 2013, 6, 274-281.	1.1	109
32	Sustained Benefit at 2ÂYears for Covered Stents Versus Bare-Metal Stents in Long SFA Lesions: The VIASTAR Trial. CardioVascular and Interventional Radiology, 2015, 38, 25-32.	0.9	100
33	Two-Year Results after Directional Atherectomy of Infrapopliteal Arteries with the SilverHawk Device. Journal of Endovascular Therapy, 2007, 14, 232-240.	0.8	83
34	Drug-Eluting Balloon Therapy for Femoropopliteal Occlusive Disease. Journal of Endovascular Therapy, 2015, 22, 727-733.	0.8	82
35	Safety and Feasibility of Intravascular Lithotripsy for Treatment of Below-the-Knee Arterial Stenoses. Journal of Endovascular Therapy, 2018, 25, 499-503.	0.8	81
36	Superiority of Stent-Grafts for In-Stent Restenosis in the Superficial Femoral Artery. Journal of Endovascular Therapy, 2015, 22, 1-10.	0.8	80

#	Article	IF	Citations
37	Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease. Journal of Endovascular Therapy, 2016, 23, 701-707.	0.8	80
38	Current practice of first-line treatment strategies in patients with critical limb ischemia. Journal of Vascular Surgery, 2015, 62, 965-973.e3.	0.6	79
39	Endovascular Therapy Versus Bypass Surgery as First-Line Treatment Strategies for Critical Limb Ischemia. JACC: Cardiovascular Interventions, 2016, 9, 2557-2565.	1.1	77
40	High-Grade, Non-Flow-Limiting Dissections Do Not Negatively Impact Long-term Outcome After Paclitaxel-Coated Balloon Angioplasty: An Additional Analysis From the THUNDER Study. Journal of Endovascular Therapy, 2013, 20, 792-800.	0.8	74
41	Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. European Heart Journal, 2016, 37, 1096-1103.	1.0	73
42	Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain. JACC: Cardiovascular Interventions, 2018, 11, 945-953.	1.1	71
43	Nitinol Stent Implantation in the Superficial Femoral Artery and Proximal Popliteal Artery: Twelve-Month Results From the Complete SE Multicenter Trial. Journal of Endovascular Therapy, 2014, 21, 202-212.	0.8	65
44	Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up. CardioVascular and Interventional Radiology, 2017, 40, 1832-1838.	0.9	60
45	Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 2113-2123.	1.1	60
46	Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent. CardioVascular and Interventional Radiology, 2021, 44, 368-375.	0.9	55
47	Heparin-Bonded Stent-Graft for the Treatment of TASC II C and D Femoropopliteal Lesions: The Viabahn-25 cm Trial. Journal of Endovascular Therapy, 2014, 21, 765-774.	0.8	51
48	Economic analysis of endovascular interventions for femoropopliteal arterial disease: A systematic review and budget impact model for the United States and Germany. Catheterization and Cardiovascular Interventions, 2014, 84, 546-554.	0.7	51
49	Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease. Circulation: Cardiovascular Interventions, 2018, 11, e005654.	1.4	51
50	One-Year Outcomes Following Directional Atherectomy of Infrapopliteal Artery Lesions. Journal of Endovascular Therapy, 2015, 22, 839-846.	0.8	48
51	One-Year Results of First-Line Treatment Strategies in Patients With Critical Limb Ischemia (CRITISCH) Tj ETQq1 1 0.784314 rgBT /Ove	0.8	42
52	Primary Self-EXPANDing Nitinol Stenting vs Balloon Angioplasty With Optional Bailout Stenting for the Treatment of Infrapopliteal Artery Disease in Patients With Severe Intermittent Claudication or Critical Limb Ischemia (EXPAND Study). Journal of Endovascular Therapy, 2015, 22, 690-697.	0.8	40
53	Stellarex drugâ€coated balloon for treatment of femoropopliteal arterial diseaseâ€”The <scp>ILLUMENATE</scp> Global Study: 12â€Month results from a prospective, multicenter, singleâ€arm study. Catheterization and Cardiovascular Interventions, 2018, 91, 497-504.	0.7	40
54	Drug-Coated Balloon Treatment forÂFemoropopliteal Artery Disease. JACC: Cardiovascular Interventions, 2019, 12, 484-493.	1.1	37

#	Article	IF	Citations
55	Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort. Journal of Endovascular Therapy, 2020, 27, 693-705.	0.8	34
56	Outcomes of dialysis patients with critical limb ischemia after revascularization compared with patients with normal renal function. Journal of Vascular Surgery, 2018, 68, 822-829.e1.	0.6	32
57	Six-Month Outcomes From the First-in-Human, Single-Arm SELUTION Sustained-Limus-Release Drug-Eluting Balloon Trial in Femoropopliteal Lesions. Journal of Endovascular Therapy, 2020, 27, 683-690.	0.8	32
58	Helical Centerline Stent Improves Patency. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	30
59	Disease Burden and Clinical Outcomes Following Initial Diagnosis of Critical Limb Ischemia in the Medicare Population. JACC: Cardiovascular Interventions, 2018, 11, 1011-1012.	1.1	30
60	Outcomes After Drug-Coated Balloon Treatment of Femoropopliteal Lesions in Patients With Critical Limb Ischemia: A Post Hoc Analysis From the IN.PACT Global Study. Journal of Endovascular Therapy, 2019, 26, 305-315.	0.8	27
61	Balloon Angioplasty of Infrapopliteal Arteries: A Systematic Review and Proposed Algorithm for Optimal Endovascular Therapy. Journal of Endovascular Therapy, 2020, 27, 547-564.	0.8	27
62	Drug-coated Balloon Angioplasty of Femoropopliteal Lesions Maintained Superior Efficacy over Conventional Balloon: 2-year Results of the Randomized EffPac Trial. Radiology, 2020, 295, 478-487.	3.6	27
63	Paclitaxel and Mortality: The Dose Argument Is Critical. Journal of Endovascular Therapy, 2019, 26, 467-470.	0.8	24
64	Evaluation of Mortality Following Paclitaxel Drug-Coated Balloon Angioplasty of Femoropopliteal Lesions in the Real World. JACC: Cardiovascular Interventions, 2020, 13, 2052-2061.	1.1	24
65	Novel Nitinol Stent for Lesions up to 24 cm in the Superficial Femoral and Proximal Popliteal Arteries: 24-Month Results From the TIGRIS Randomized Trial. Journal of Endovascular Therapy, 2018, 25, 68-78.	0.8	23
66	Treatment of infrapopliteal postâ€PTA dissection with tack implants: 12â€month results from the TOBAâ€BTK study. Catheterization and Cardiovascular Interventions, 2018, 92, 96-105.	0.7	20
67	Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Stented Renal Arteries. Circulation: Cardiovascular Interventions, 2014, 7, 813-820.	1.4	19
68	IN.PACT Amphirion paclitaxel eluting balloon versus standard percutaneous transluminal angioplasty for infrapopliteal revascularization of critical limb ischemia: rationale and protocol for an ongoing randomized controlled trial. Trials, 2014, 15, 63.	0.7	19
69	Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial. Journal of Endovascular Therapy, 2020, 27, 276-286.	0.8	17
70	Propensity Scoreâ€“Adjusted Comparison of Long-Term Outcomes Among Revascularization Strategies for Critical Limb Ischemia. Circulation: Cardiovascular Interventions, 2019, 12, e008097.	1.4	16
71	Efficacy and safety of a novel paclitaxel-nano-coated balloon for femoropopliteal angioplasty: one-year results of the EffPac trial. EuroIntervention, 2020, 15, e1633-e1640.	1.4	16
72	Intravascular Lithotripsy for Peripheral Artery Calcification: Mid-term Outcomes From the Randomized Disrupt PAD III Trial. , 2022, 1, 100341.		15

#	Article	IF	Citations
73	Real-World Experience With a Paclitaxel-Coated Balloon in Critical Limb Ischemia. JACC: Cardiovascular Interventions, 2020, 13, 2289-2299.	1.1	12
74	Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain. Circulation: Cardiovascular Interventions, 2019, 12, e007730.	1.4	10
75	Heparin-Bonded Stent-Graft for the Treatment of TASC II C and D Femoropopliteal Lesions: 36-Month Results of the Viabahn 25 cm Trial. Journal of Endovascular Therapy, 2021, 28, 222-228.	0.8	10
76	Digital Subtraction Angiography Prior to an Amputation for Critical Limb Ischemia (CLI): An Expert Recommendation Statement From the CLI Global Society to Optimize Limb Salvage. Journal of Endovascular Therapy, 2020, 27, 540-546.	0.8	9
77	Bypass Grafting vs Endovascular Therapy in Patients With Non-Dialysis-Dependent Chronic Kidney Disease and Chronic Limb-Threatening Ischemia (CRITISCH Registry). Journal of Endovascular Therapy, 2020, 27, 599-607.	0.8	9
78	The SELUTION SLRâ„¢ drug-eluting balloon system for the treatment of symptomatic femoropopliteal lesions. Future Cardiology, 2021, 17, 257-267.	0.5	9
79	Orbital Atherectomy Prior to Drug-Coated Balloon Angioplasty in Calcified Infrapopliteal Lesions: A Randomized, Multicenter Pilot Study. Journal of Endovascular Therapy, 2022, 29, 874-884.	0.8	9
80	Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent. CardioVascular and Interventional Radiology, 2021, 44, 196-206.	0.9	7
81	Head-to-head comparison of sirolimus- versus paclitaxel-coated balloon angioplasty in the femoropopliteal artery: study protocol for the randomized controlled SIRONA trial. Trials, 2021, 22, 665.	0.7	7
82	2-Year Results With a Sirolimus-ElutingÂSelf-Expanding StentÂfor Femoropopliteal Lesions. JACC: Cardiovascular Interventions, 2022, 15, 618-626.	1.1	7
83	Treatment of Femoropopliteal Lesions With the BioMimics 3D Vascular Stent System: Two-Year Results From the MIMICS-2 Trial. Journal of Endovascular Therapy, 2021, 28, 236-245.	0.8	6
84	Photoablative atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis in instent femoro-popliteal obstructions (PHOTOPAC). Vasa - European Journal of Vascular Medicine, 2021, 50, 387-393.	0.6	6
85	Two-year Review on Mortality and Morbidity after Femoropopliteal Drug-coated Balloon Angioplasty in the Randomized EffPac Trial. Radiology, 2020, 296, 638-640.	3.6	5
86	Contralateral Stenosis and Echolucent Plaque Morphology are Associated with Elevated Stroke Risk in Patients Treated with Asymptomatic Carotid Artery Stenosis within a Controlled Clinical Trial (SPACE-2). Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105940.	0.7	5
87	Modern multidisciplinary team approach is crucial in treatment for critical limb threatening ischemia. Journal of Cardiovascular Surgery, 2021, 62, 124-129.	0.3	3
88	Individual patient data metaâ€analysis of patients treated with a heparinâ€bonded Viabahn in the femoropopliteal artery for chronic limbâ€threatening ischemia. Catheterization and Cardiovascular Interventions, 2022, , .	0.7	2
89	Femoropopliteal Drug-coated Balloon Angioplasty: Long-term Results of the Randomized EffPac Trial. Radiology, 2022, , 212622.	3.6	1
90	Successful Secondary Endovascular Intervention in Pediatric Patients with Venous Thromboembolic Events. Hamostaseologie, 2022, , .	0.9	0

#	ARTICLE	IF	CITATIONS
91	Time for a Standardized Common Femoral Artery Classification System. CardioVascular and Interventional Radiology, 2022, 45, 448-449.	0.9	0